Empagliflozin/Linagliptin and Topiramate Interaction

Drug interaction information between Empagliflozin/Linagliptin and Topiramate.

Empagliflozin/Linagliptin and Topiramate have a documented minor interaction in FDA labeling.

FDA drug labeling documents a minor-severity interaction between Empagliflozin/Linagliptin and Topiramate. This page displays the available source-record category and label text. The category is not an individual risk estimate or medication-combination direction.

Drug A

Empagliflozin/Linagliptin

SGLT2 / DPP-4 Combination

Drug B

Topiramate

Anticonvulsant

How They Interact

Topiramate can lower the levels of certain chemicals that keep your blood from becoming too acidic. This can lead to a dangerous acid buildup in the body.

Empagliflozin/Linagliptin Also Interacts With

View all Empagliflozin/Linagliptin interactions →

Frequently Asked Questions

What SPL severity band is on file for Empagliflozin/Linagliptin + Topiramate?

Compiled FDA labeling labels this pair minor. That is a source-record field, not an individual medication-combination decision.

Which drug in this pair has the larger labeled-interaction portfolio?

Topiramate has 30 labeled pairs on file vs Empagliflozin/Linagliptin's 11. In the minor band specifically: Empagliflozin/Linagliptin has 7 (also Empagliflozin, Lithium, Rifampin, Linagliptin); Topiramate has 27 (also Hydrochlorothiazide, Amitriptyline, Pioglitazone, Carbamazepine).

What mechanism field is on file for Empagliflozin/Linagliptin and Topiramate?

Topiramate can lower the levels of certain chemicals that keep your blood from becoming too acidic. This can lead to a dangerous acid buildup in the body.

Topiramate's labeled portfolio outnumbers Empagliflozin/Linagliptin

SPL source-record counts only. This page's band is minor · classes on file: Empagliflozin/Linagliptin (SGLT2 / DPP-4 Combination); Topiramate (Anticonvulsant).

Empagliflozin/Linagliptin

0 major · 4 moderate · 7 minor · 11 total

Topiramate

0 major · 3 moderate · 27 minor · 30 total

Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. This registry does not provide individual medication-combination directions.